Aspire Biopharma Holdings, Inc. (ASBP) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company focused on developing novel sublingual delivery mechanisms for drugs and supplements. The company completed a reverse recapitalization business combination with PowerUp Acquisition Corp. on February 17, 2025. As of the reporting date, the company has no commercial revenue and is in the pre-revenue development stage.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,981,293) | $(17,922,621) |
| Operating Expenses | $(799,890) | $(16,356,370) |
| Cash and Cash Equivalents | $206,233 | $206,233 |
| Total Current Liabilities | $10,556,922 | $10,556,922 |
| Working Capital Deficit | $(9,567,500) | $(9,567,500) |
| Accumulated Deficit | $(20,699,854) | $(20,699,854) |
Debt and Liquidity: The company holds significant debt obligations, including $3,617,508 in convertible notes, $2,025,344 in subscription agreement loans, and $1,331,357 in related party notes payable. Cash flow from operations was negative $(2,891,838) for the six months ended June 30, 2025, while financing activities provided $3,094,438.
Material Changes vs. Prior Period
- Explosion in Operating Expenses: General and administrative expenses surged to $15.47 million for the six months ended June 30, 2025, compared to $219,227 in the prior year period. This increase is primarily driven by a one-time stock-based compensation charge of $14.13 million related to the business combination.
- Non-Operating Losses: The company recorded significant non-operating losses in 2025 not present in 2024, including $817,824 in interest expense, $384,318 in changes in fair value of derivative liabilities, and $364,109 in loss on extinguishment of debt.
- Balance Sheet Deterioration: Total liabilities increased from $1.69 million at December 31, 2024, to $10.61 million at June 30, 2025, largely due to the assumption of debt and issuance of convertible notes in connection with the business combination.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has determined that the company's liquidity condition raises substantial doubt about its ability to continue as a going concern for twelve months from the date of issuance. The company requires additional financing to fund operations.
- Nasdaq Compliance Deficiencies: On April 16, 2025, the company received notices from Nasdaq regarding non-compliance with the Minimum Market Value of Listed Securities ($50 million) and Minimum Bid Price ($1.00) rules. The company has 180 days (until October 13, 2025) to regain compliance or face delisting.
- Debt Settlement: The company entered into a settlement agreement in April 2025 to resolve default notices from lenders (Cobra Alternative Capital Strategies and Blackstone Capital Advisors), extending maturity dates and issuing 625,000 shares of common stock.
- Leadership Changes: In July 2025, CEO Michael Howe and two directors stepped down. Kraig Higginson was appointed Interim CEO. The company is searching for a permanent CEO.
- Product Pipeline: The company is developing sublingual aspirin (Instaprin), caffeine products, and other formulations. A clinical trial for aspirin concluded in July 2025, with results expected in August 2025. Caffeine products are planned for launch in Q3 2025.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure immediate equity or debt financing to cover the $9.57 million working capital deficit.
- Nasdaq Delisting Risk: Monitor the company's progress in meeting the $50 million market value and $1.00 bid price requirements by October 13, 2025.
- Debt Maturities: Review the specific maturity dates of the convertible notes and subscription loans, many of which have been extended to August and September 2025.
- Stock-Based Compensation: Confirm the impact of the $14.13 million non-cash expense on the reported net loss and future dilution.
- Management Stability: Assess the timeline for appointing a permanent CEO following the recent departure of the CEO and directors.